|
ATE205202T1
(de)
|
1992-03-13 |
2001-09-15 |
Merck Sharp & Dohme |
Imidazol-, triazol- und tetrazolderivate
|
|
GB9207396D0
(en)
|
1992-04-03 |
1992-05-13 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US5952294A
(en)
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
|
EP1399467A4
(en)
|
2001-05-09 |
2004-09-15 |
Newbiotics Inc |
PRODRUGS ACTIVATED BY PEPTIDDEFORMYLASE
|
|
US6642390B2
(en)
|
2001-07-11 |
2003-11-04 |
Lexicon Pharmaceuticals, Inc. |
One step synthesis of 1,2,3-triazole carboxylic acids
|
|
DE60222698T2
(de)
|
2001-12-18 |
2008-06-19 |
Merck & Co., Inc. |
Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
|
|
JP2005529889A
(ja)
|
2002-04-26 |
2005-10-06 |
ファイザー・プロダクツ・インク |
ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
|
|
US7354938B2
(en)
|
2004-03-23 |
2008-04-08 |
Amgen Inc. |
Pyrazole compounds and uses related thereto
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
JP4734346B2
(ja)
|
2005-02-04 |
2011-07-27 |
セノミックス インコーポレイテッド |
連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
|
|
US7618962B2
(en)
*
|
2005-02-25 |
2009-11-17 |
Pgx Health, Llc |
Pyrazolyl substituted xanthines
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007109547A2
(en)
*
|
2006-03-17 |
2007-09-27 |
Cv Therapeutics, Inc. |
Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
|
|
US20080032992A1
(en)
|
2006-07-04 |
2008-02-07 |
Astrazeneca Ab |
New Pyridine Analogues V
|
|
US7994321B2
(en)
|
2006-08-08 |
2011-08-09 |
Hoffmann-La Roche Inc. |
Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2249853A4
(en)
|
2008-01-30 |
2012-12-26 |
Univ Indiana Res & Tech Corp |
ESTER BASED PEPTIDE PRODRUGS
|
|
PE20091953A1
(es)
|
2008-05-08 |
2010-01-09 |
Du Pont |
Azoles sustituidos como fungicidas
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US9643922B2
(en)
|
2008-08-18 |
2017-05-09 |
Yale University |
MIF modulators
|
|
US20120040974A1
(en)
|
2008-08-18 |
2012-02-16 |
Yale University |
Mif modulators
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
RU2528412C2
(ru)
*
|
2009-02-10 |
2014-09-20 |
Янссен Фармацевтика Нв |
Хиназолиноны как ингибиторы пролилгидроксилазы
|
|
US8969342B2
(en)
|
2009-03-20 |
2015-03-03 |
Brandeis University |
Compounds and methods for treating mammalian gastrointestinal microbial infections
|
|
US8193235B2
(en)
|
2009-06-12 |
2012-06-05 |
University Of Kansas |
Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
|
|
EP2451286B8
(en)
|
2009-07-08 |
2018-04-04 |
ISP Investments LLC |
4- and 5 substituted 1,2,3- triazole moieties with at least one remote polymerizable moiety and polymers thereof
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
WO2011050284A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Pyrazolylpyridine antiviral agents
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
WO2011089215A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
CN102918034B
(zh)
|
2010-03-30 |
2015-06-03 |
维颂公司 |
多取代芳族化合物作为凝血酶的抑制剂
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
US8748435B2
(en)
|
2011-04-01 |
2014-06-10 |
Novartis Ag |
Pyrazolo pyrimidine derivatives
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013085890A1
(en)
|
2011-12-06 |
2013-06-13 |
Glaxo Group Limited |
Therapeutic methods
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
RU2627268C2
(ru)
|
2012-02-29 |
2017-08-04 |
Хемоцентрикс, Инк. |
Аза-арил-1Н-пиразол-1-ил-сульфонамиды
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
DE102012102162A1
(de)
|
2012-03-14 |
2013-09-19 |
Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts |
Ionenleitende polymere Verbindung für elektrochemische Zellen
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014153100A2
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2015031824A1
(en)
|
2013-08-30 |
2015-03-05 |
Icahn School Of Medicine At Mount Sinai |
Cyclic vinylogous amides as bromodomain inhibitors
|
|
EP2903044A1
(de)
|
2014-02-04 |
2015-08-05 |
cynora GmbH |
Organische Moleküle zur Verwendung in optoelektronischen Bauelementen
|
|
EP3137074B1
(en)
|
2014-04-29 |
2020-08-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
US20160251341A1
(en)
|
2015-02-27 |
2016-09-01 |
Verseon Corporation |
Substituted triazole compounds as serine protease inhibitors
|
|
CN108472284A
(zh)
|
2015-09-11 |
2018-08-31 |
维纳拓尔斯制药公司 |
β-内酰胺酶抑制剂
|
|
HUE064141T2
(hu)
|
2017-01-20 |
2024-02-28 |
Arcus Biosciences Inc |
Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
|
|
ES2953349T3
(es)
*
|
2017-05-05 |
2023-11-10 |
Arcus Biosciences Inc |
Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
|